IP Library Granted Patent US 10,702,551
Granted Patent B2
US 10,702,551 · App. 16/155,801 · Granted Jul 7, 2020

Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse

Inventor: Matthias Stephan (Seattle, WA)
Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
A61K35/17A01K67/0271A61K9/0024A61K9/146A61K39/44A61K45/06C07K16/2809C07K16/2818C07K16/2878C12N5/0694A01K2207/12A01K2227/105A01K2267/0331C12N2510/00C12N2533/54C12N2533/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,702,551
App. No.
16/155,801
Granted
Jul 7, 2020
Kind
B2
Abstract

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

Claims (9)

1. An alginate polymer scaffold coated with a synthetic collagen-mimetic peptide comprising SEQ ID NO: 2, wherein the scaffold houses: porous silica microparticles with a pore diameter of about 100 Å and wherein the microparticles are (a) coated with anti-CD3 antibodies and anti-CD28 antibodies and (b) loaded with interleukin 15.

2. A composition comprising (i) an injectable alginate polymer or an implantable alginate polymer scaffold comprising pores; and (ii) SEQ ID NO: 2, anti-CD3 antibodies, anti-CD28 antibodies, and interleukin 15.

3. The composition of claim 2 , further comprising lymphocytes.

4. The composition of claim 2 , wherein the anti-CD3 antibodies and anti-CD28 antibodies are bound to or incorporated in one or more particles.

5. The composition of claim 2 , further comprising anti-CD137 antibodies.

6. The composition of claim 2 , wherein the alginate polymer is injectable.

7. The composition of claim 2 , wherein the alginate polymer is an implantable scaffold, and the SEQ ID NO: 2 is associated with the scaffold in a bioactive coating on the scaffold.

8. The composition of claim 2 , wherein the alginate polymer is an implantable scaffold, and the anti-CD3 antibodies and anti-CD28 antibodies are associated with particles embedded in the pores of the scaffold.

9. The composition of claim 2 , wherein the alginate polymer is an implantable scaffold and the anti-CD3 antibodies and anti-CD28 antibodies are associated with particles attached to the surface of the scaffold or are embedded in the scaffold.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2025
From: STEPHAN, MATTHIAS
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 073321/0645 →
MERGER AND CHANGE OF NAME Recorded Jun 22, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060434/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: STEPHAN, MATTHIAS
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 048113/0191 →
Continuity (4)
Continuation 14760695
Provisional Application 61900922 · Nov 6, 2013
Provisional Application 61752423 · Jan 14, 2013
Related Publication 20190054121A1 · Feb 21, 2019
Cited By (3)
US 12,472,148 US 12,502,360 US 12,649,932